FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma

European Journal of Pharmacology - Tập 931 - Trang 175186 - 2022
Xiang-Peng Tan1, Ben-Han Xiong2, Yuan-Xu Zhang2, Shen-Li Wang3, Qian Zuo4, Jing Li5
1The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China
2College of Life Science and Technology, Jinan University, Guangzhou, China
3The Biomedical Translational Research Institute, Jinan University, Guangzhou, China
4Department of Breast Disease, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
5The First Hospital of Hunan University of Chinese Medicine, Changsha, China

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

European Journal of Pharmacology

Tập 931

175186

Thông tin tác giả